Solution formulation development of a VEGF inhibitor for intravitreal injection

AAPS PharmSciTech

Volumn 12, Issue 1, 2011, Pages 362-371

  Marra, Michelle T ^a   Khamphavong, Penney ^a   Wisniecki, Peter ^a   Gukasyan, Hovhannes J ^a   Sueda, Katsuhiko ^b  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

AMD; depot; ophthalmic; parenteral; sustained delivery

Indexed keywords

BUFFER; HYPERTONIC SOLUTION; ISOTONIC SOLUTION; PF 00337210; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ARTICLE; CHEMICAL COMPOSITION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PH; PRECIPITATION; PRIORITY JOURNAL; VITREOUS BODY;

ANIMALS; BENZOFURANS; BUFFERS; DOGS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; HUMANS; HYDROGEN-ION CONCENTRATION; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL SOLUTIONS; PROTEIN KINASE INHIBITORS; QUINOLINES; RABBITS; SOLUBILITY; SUSPENSIONS; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITREOUS BODY;

EID: 79954425670     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9591-4     Document Type: Article

References (36)

1. S Duvvuri S Majumdar AK Mitra 2003 Drug delivery to the retina: challenges and opportunities Expert Opin Biol Ther 3 1 45 56 12718730 10.1517/14712598.3.1.45 1:CAS:528:DC%2BD3sXislKnurY%3D (Pubitemid 36193650)
2. D Ghate HF Edelhauser 2006 Ocular drug delivery Expert Opin Drug Deliv 3 2 275 287 16506953 10.1517/17425247.3.2.275 1:CAS:528:DC%2BD28XhvVKnsLc%3D (Pubitemid 43338097)
3. A Urtti 2006 Challenges and obstacles of ocular pharmacokinetics and drug delivery Adv Drug Deliv Rev 58 11 1131 1135 17097758 10.1016/j.addr.2006.07.027 1:CAS:528:DC%2BD28Xht1CnsL3M
4. C Durairaj JC Shah D Senapati UB Kompella 2009 Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR) Pharm Res 26 5 1236 1260 18841448 10.1007/s11095-008-9728-7 1:CAS:528:DC%2BD1MXlsVekug%3D%3D
5. M Barza A Kane J Baum 1983 Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys Invest Ophthalmol Vis Sci 24 12 1602 1606 6654640 1:CAS:528:DyaL2cXnvFCnsg%3D%3D (Pubitemid 14220955)
6. I Cochereau-Massin S Marrakchi-Benjaafar J Bauchet JM Vallois F Faurisson, et al. 1994 Kinetics and tolerability of intravitreal pefloxacin in rabbits J Antimicrob Chemother 33 2 231 242 8182004 10.1093/jac/33.2.231 1:CAS:528:DyaK2cXjtFGhsL8%3D (Pubitemid 24076802)
7. D Maurice 2001 Review: practical issues in intravitreal drug delivery J Ocul Pharmacol Ther 17 4 393 401 11572470 10.1089/108076801753162807 1:CAS:528:DC%2BD3MXntFWntLs%3D (Pubitemid 32888812)
8. LG Presta H Chen SJ O'connor V Chisholm YG Meng L Krummen, et al. 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 20 4593 4599 9377574 1:CAS:528:DyaK2sXmslKqtLg%3D (Pubitemid 27441066)
9. N Ferrara KJ Hillan HP Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 391 400 15136787 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D (Pubitemid 38618122)
10. J Folkman Y Shing 1992 Angiogenesis J Biol Chem 267 16 10931 10934 1375931 1:CAS:528:DyaK38XksVSmu7s%3D
11. M Klagsbrun PA D'Amore 1991 Regulators of angiogenesis Ann Rev Physiol 53 217 239 10.1146/annurev.ph.53.030191.001245 1:CAS:528:DyaK3MXlt1Ohsb8%3D
12. N Congdon B O'Colmain CCW Klaver R Klein B Munoz DS Friedman, et al. 2004 Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 4 477 485 15078664 10.1001/archopht.122.4.477 (Pubitemid 38456282)
13. N Ferrara 2009 VEGF-A: a critical regulator of blood vessel growth Eur Cytokine Netw 20 4 158 163 20167554 1:CAS:528:DC%2BC3cXns1Ol
14. SJ McGimpsey U Chakravarthy 2010 VEGF-targeted therapy and beyond; pharmacotherapy and emerging treatments in age-related macular degeneration Expert Rev Clin Pharmacol 3 2 243 252 10.1586/ecp.10.6 1:CAS:528: DC%2BC3cXjtVOqtbY%3D
15. PJ Rosenfeld DM Brown JS Heier DS Boyer PK Kaiser CY Chung, et al. 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 1419 1431 17021318 10.1056/NEJMoa054481 1:CAS:528:DC%2BD28XhtVGgtr3M (Pubitemid 44511557)
16. JS Heier AN Antoszyk PR Pavan SR Leff PJ Rosenfeld TA Ciulla, et al. 2006 Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study Ophthalmology 113 4 633.e1 633.e4 10.1016/j.ophtha.2005.10.052
17. ZF Bashshur A Bazarbachi A Schakal ZA Haddad H El P Christelle, et al. 2006 Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 142 1 e1 e9 10.1016/j.ajo.2006.02.037 (Pubitemid 43946791)
18. RL Avery DJ Pieramici MD Rabena AA Castellarin MA Nasir MJ Giust 2006 Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 3 363.e5 372.e5 10.1016/j.ophtha.2005.11.019
19. MR Barakat PK Kaiser 2009 VEGF inhibitors for the treatment of neovascular age-related macular degeneration Expert Opin Investig Drugs 18 5 637 646 19388880 10.1517/13543780902855316 1:CAS:528:DC%2BD1MXkvFChurg%3D
20. MA Figueroa I Contreras S Noval 2009 Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy Curr Diabetes Rev 5 52 56 19199899 10.2174/157339909787314202 1:CAS:528: DC%2BC3cXislyitLw%3D
21. RL Avery J Pearlman DJ Pieramici MD Rabena AA Castellarin MA Nasir 2006 Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 10 1695.e1 1695.e15 10.1016/j.ophtha.2006.05.064 (Pubitemid 44442453)
22. Marrone TJ, Hu-Lowe DD, Grazzini M, Yin MJ, Chen J, Hallin M, et al. PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; AACR Meeting Abstracts; 2007 Apr 14-18; Los Angeles, CA 2007. Abstract nr 3992.
23. Abram D. Current perspectives on aseptic formulation: a practical guide to process development and validation. Pharmaceutical Technology 2009; Suppl. S10-S12: S14-S15.
24. White E. Risk management for aseptic processing. Pharmaceutical Technology 2009; (Suppl.): S16-22.
25. GW Lu 2010 Recent advances in developing ophthalmic formulations: a patent review Recent Pat Drug Deliv Formul 4 1 49 57 19807679 10.2174/187221110789957246 1:CAS:528:DC%2BC3cXisVKmuro%3D
26. SA Aguirre W Collette III H Younis HJ Gukasyan W Huang 2010 Ocular effects of maleic acid administration in rabbits following intravitreal injection Invest Ophthalmol Vis Sci 51 E-Abstract 5105
27. C Durairaj SJ Kim HF Edelhauser JC Shah UB Kompella 2009 Influence of dosage form on the intravitreal pharmacokinetics of diclofenac Invest Ophthalmol Vis Sci 50 10 4887 4897 19516015 10.1167/iovs.09-3565
28. Pohl R, Kashyap N, Hauser R, Ozhan K, Steiner SS, inventors; Biodel Inc, assignee. Insulin with basal release profile. International Application Number PCT/US2009/055746. International Publication number PCT Int. Appl. WO 2010/028055 A1, 2010 March.
29. Jain R, Jindal KC, Devarajan SK, inventors. Jain R, Jindal KC, Panacea Biotec LTD, Devarajan SK, assignee. Injectable depot compositions for tamsulosin or letrozole. PCT Int. Appl. WO08041246 A2, 2008 April.
30. Z Jiang J Hao Y You Q Gu W Cao X Deng 2009 Biodegradable thermogelling hydrogel of P(CL-GL)-PEG-P(CL-GL) triblock copolymer: degradation and drug release behavior J Pharm Sci 98 8 2603 2610 19455626 10.1002/jps.21613 1:CAS:528:DC%2BD1MXns1eqsbo%3D
31. HC Evans AJ Wagstaff 2004 Leuprorelin: subcutaneous depot formulation (Eligard) for advanced prostate cancer Am J Cancer 3 3 197 201 10.2165/00024669-200403030-00008 1:CAS:528:DC%2BD2cXosF2rs7Y%3D (Pubitemid 39221970)
32. NS Zeidner RF Massung MC Dolan E Dadey E Gabitzsch G Dietrich, et al. 2008 A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite J Med Microbiol 57 4 463 468 18349366 10.1099/jmm.0.47535-0 1:CAS:528:DC%2BD1cXlslWlt7s%3D (Pubitemid 351537021)
33. Schoenhammer K, inventor, Novartis AG, assignee. Pharmaceutical compositions containing less than 600 Dalton polyethylene glycol for injectable in situ-forming depots. PCT Int. Appl. WO 2010/018159 A1, 2010 Feb.
34. M Marra HJ Gukasyan S Raghava UB Kompella 2007 Second ophthalmic drug development and delivery summit Expert Opin Drug Deliv. 4 1 77 85 17184164 10.1517/17425247.4.1.77 (Pubitemid 46117488)
35. Martin A, Bustamande P. Physical pharmacy. 4th ed. Philadelphia: Lea & Febiger; 1993. p. 173-4.
36. Perrin DD, Dempsey B. Buffers for pH and metal ion control. London: Chapman and Hall; 1979. p. 10-2.